Biotech Firm Curis Hits 52-Week Stock Low Curis Inc., a biotech company, saw its stock price drop to a 52-week low of $2.83, reflecting a 70% annual decline. The company faces challenges, including potential Nasdaq delisting due to market value non-compliance, while investors await progress in its drug development pipeline and financial recovery.2